In August 2023, we published an in-depth article that focused on a significant improvement in the treatment of both heart and kidney diseases coming from the widespread introduction of new diabetes medications that are based on GLP-1 (glucagon-like peptide-1) receptor agonists (such as Ozempic, Semaglutide, and Mounjaro.) One of our readers posted a question as to whether other new diabetes medications that are based on SGLT2 inhibitors (such as Farxiga) can produce results similar results. While we briefly mentioned SGLT2i in the original article, we would like to revisit the conversation now and provide a bit more focus on Farxiga and other similar drugs.
For more details on GLP-1, please see “Mounjaro is hot news, for good reason,” “Your guide to compounded medications” and “Good News about Semaglutide Side Effects)”. These each offer insight into how GLP-1-based drugs have revolutionized treatments in several fields, including diabetes, obesity, heart disease, and kidney failure.
Five common misbeliefs about COVID-19 and vaccines
Do people let false claims about health issues get in their way? It is quite disturbing to learn that reliable
Read More »